Rigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024. In the quarter to June 2026, revenue fell 22.6%, EPS fell 72.1%, free cash flow fell 230.0% and total debt fell 66.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow RIGL
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
95.33 | 146.68 | 154.96 | 137.14 |
+8 more quarters Free account |
Receivables |
56.04 | 49.95 | 51.76 | 45.93 | |
Inventory |
14.37 | 11.65 | 11.51 | 13.30 | |
Total current assets |
185.53 | 234.03 | 240.17 | 214.93 | |
Property, Plant, Equpment (Net) |
— | — | — | 0.05 | |
Goodwill and Intangible Assets (Total) |
93.88 | 24.16 | 24.75 | 25.34 | |
Long Term Assets (Tax, Deferred) |
238.07 | 243.28 | 245.85 | — | |
Long-term assets (Other) |
2.94 | 2.36 | 1.91 | 1.17 | |
Total non-current assets |
335.54 | 270.58 | 273.43 | 27.61 | |
Total Assets |
521.07 | 504.61 | 513.59 | 242.53 | |
Notes Payable |
39.24 | 29.87 | 29.81 | 29.76 | |
Accounts Payable |
4.01 | 4.49 | 7.19 | 3.85 | |
Accrued Expenses |
15.54 | 11.75 | 17.44 | 14.88 | |
Current Revenue (Deferred) |
— | — | — | 1.36 | |
Other current liabilities |
28.19 | 33.08 | 32.72 | 35.02 | |
Total current liabilities |
95.59 | 89.49 | 99.24 | 94.40 | |
Long Term Debt (Total) |
— | 14.99 | 22.48 | 29.97 | |
Total non-current liabilities |
0.06 | 15.22 | 22.88 | 30.53 | |
Total liabilities |
95.64 | 104.71 | 122.11 | 124.93 | |
Additional Paid In Capital |
1,422.65 | 1,414.39 | 1,414.32 | 1,408.60 | |
Common Stock (Net) |
0.02 | 0.02 | 0.02 | 0.02 | |
Retained Earnings |
(997.10) | (1,014.39) | (1,023.04) | (1,291.11) | |
Common Equity (Total) |
425.42 | 399.90 | 391.48 | 117.61 | |
Shareholders Equity (Total) |
425.42 | 399.90 | 391.48 | 117.61 | |
Shareholders Equity and Liabilities (Total) |
521.07 | 504.61 | 513.59 | 242.53 | |
Shares (Common) |
18.65 | 18.48 | 18.31 | 18.14 | |
Shareholders Equity (Tangible) |
331.54 | 375.74 | 366.73 | 92.27 | |
Net Debt |
(95.33) | (131.69) | (132.47) | (107.17) | |
Total Debt |
— | 14.99 | 22.48 | 29.97 |